Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    BK1310-J02
Previous Study | Return to List | Next Study

Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03188692
Recruitment Status : Completed
First Posted : June 15, 2017
Last Update Posted : February 6, 2019
Sponsor:
Collaborator:
The Research Foundation for Microbial Diseases of Osaka University
Information provided by (Responsible Party):
Mitsubishi Tanabe Pharma Corporation

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of an intramuscular injection of BK1310 in healthy infants.

Condition or disease Intervention/treatment Phase
Immunization Biological: DPT-IPV-Hib (Combined Vaccine) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase 3 Study of BK1310 Intramuscular Injection in Healthy Infants
Actual Study Start Date : June 23, 2017
Actual Primary Completion Date : November 2, 2017
Actual Study Completion Date : August 9, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BK1310 Biological: DPT-IPV-Hib (Combined Vaccine)
0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Other Name: BK1310




Primary Outcome Measures :
  1. Antibody prevalence rate against anti-PRP with 1 μg/mL or higher, diphtheria toxin, pertussis, tetanus toxin, and polio virus [ Time Frame: 4 weeks after the primary immunization (Visit 4) ]

Secondary Outcome Measures :
  1. Anti-PRP antibody prevalence rate with 0.15 μg/mL or higher [ Time Frame: 4 weeks after the primary immunization (Visit 4) ]
  2. Geometric mean antibody titer of anti-PRP antibody [ Time Frame: 4 weeks after the primary immunization (Visit 4) ]
  3. Anti-PRP antibody prevalence rate with 1 μg/mL or higher [ Time Frame: 4 weeks after the booster dose (Visit 6) ]
  4. Anti-PRP antibody prevalence rate with 0.15 μg/mL or higher [ Time Frame: 4 weeks after the booster dose (Visit 6) ]
  5. Geometric mean antibody titer of anti-PRP antibody [ Time Frame: 4 weeks after the booster dose (Visit 6) ]
  6. Geometric mean antibody titer against diphtheria toxin, pertussis, tetanus toxin, and polio virus [ Time Frame: 4 weeks after the primary immunization (Visit 4) ]
  7. Antibody prevalence rate against diphtheria toxin, pertussis, tetanus toxin, and polio virus [ Time Frame: 4 weeks after the booster dose (Visit 6) ]
  8. Geometric mean antibody titer against diphtheria toxin, pertussis, tetanus toxin, and polio virus [ Time Frame: 4 weeks after the booster dose (Visit 6) ]
  9. Adverse events and adverse reactions [ Time Frame: Through the first dose (Visit 1) to 4 weeks after the booster dose (Visit 6) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Months to 43 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy infants aged ≥2 and <43 months at the first vaccination of the study drug (recommended: ≥2 and <7 months). Those who are applicable of the following conditions must be carefully observed before the enrollment: infants with known underlying disease such as cardiovascular disease, renal disease, hepatic disease, blood dyscrasia, respiratory disease or developmental disorder. Infants who developed fever within 2 days after any previous vaccination. Infants with history of convulsions.
  • Written informed consent is obtained from a legal guardian (parent)

Exclusion Criteria:

  • With past diagnosis of immunodeficiency or currently under immunosuppressive treatment
  • Have close relatives (the third degree of kinship) diagnosed with congenital immunodeficiency
  • Possibility of anaphylaxis due to food or pharmaceuticals
  • With diagnosis of thrombocytopenia and/or coagulopathy or currently under treatment of the antiplatelet agents and/or anticoagulant agents.
  • With experience of Hib infection, diphtheria, pertussis, tetanus or acute poliomyelitis
  • With experience of Hib, diphteria, pertussis, tetanus or polio vaccination.
  • Administered a live vaccine within 27 days before the first vaccination of the study drug, or inactivated vaccine or toxoid within 6 days before vaccination
  • Administered transfusion, immunosuppressant (excluding drugs for external use), or immunoglobulin formulation
  • Administered corticosteroid 2 mg/kg per day or more as prednisolone (excluding drugs for external use)
  • Participated in other studies within 12 weeks before obtaining consent
  • With the gestational age <37 weeks or weighed less than 2500 grams at birth.
  • Considered to be not eligible by the principal investigators (sub-investigators) of the enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03188692


Locations
Layout table for location information
Japan
Investigational site 1
Chiba, Japan
Investigational site 2
Tokyo, Japan
Investigational site 3
Tokyo, Japan
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
The Research Foundation for Microbial Diseases of Osaka University
Investigators
Layout table for investigator information
Study Director: General Manager Mitsubishi Tanabe Pharma Corporation

Layout table for additonal information
Responsible Party: Mitsubishi Tanabe Pharma Corporation
ClinicalTrials.gov Identifier: NCT03188692     History of Changes
Other Study ID Numbers: BK1310-J02
First Posted: June 15, 2017    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mitsubishi Tanabe Pharma Corporation:
Haemophilus influenza type b
Adsorbed Diphtheria-Purified Pertussis-Tetanus-Inactivate
poliovirus combined vaccine
Hib
DPT-IPV
Intramuscular
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs